Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Medline is expected to continue its successful track record of growth and profitability, driven by prime-vendor contracts, investments in digital transformation and automation, and expansion into international markets. The recent launch of Mpower and partnership with Symbotic further highlight its focus on efficiency and cost savings, which will likely contribute to continued economic profit and stakeholder value. Overall, MDLN presents an attractive opportunity for investors seeking a stable, high-growth company with a strong foothold in the US healthcare market and potential for global expansion.

Bears say

Medline is an established market leader in the US, with a strong domestic revenue base and a well-developed supply chain. However, its high reliance on North America and limited international presence pose a risk to future growth potential. The company's recent investments in automation and AI technology, as well as strategic partnerships and targeted M&A, may boost efficiency and productivity, but may also result in significant capital expenditures and margin pressure. Ultimately, Medline's success will depend on its ability to expand into fast-growing international markets and effectively manage its capital investments to generate economic profit and drive shareholder value.

Medline Inc (MDLN) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 24 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $49.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $49.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.